Edwards Lifesciences slides as investors digest scrapped JenaValve deal and growth reset
Edwards Lifesciences (EW) fell 3.36% to $79.41 as investors continued to reprice the company after it terminated its planned JenaValve acquisition following a federal court injunction sought by the FTC. The move extends recent pressure in the stock as the market weighs a slower M&A-driven growth path versus reliance on TAVR and newer mitral/tricuspid launches.
1. What’s driving EW lower today
Edwards Lifesciences shares traded lower as the market continued to discount a key former growth catalyst—its planned acquisition of JenaValve—after the transaction was blocked and ultimately abandoned. With the deal off the table, investors are reassessing Edwards’ longer-term expansion plans in transcatheter therapies for aortic regurgitation and the degree to which organic pipeline execution can offset the lost opportunity. (medtechdive.com)
2. The catalyst investors are focusing on: JenaValve deal terminated after FTC win
Edwards ended its pursuit of JenaValve after a U.S. district court granted an injunction in the FTC’s case to stop the acquisition. The regulatory action centered on concerns that combining the two companies would reduce competition in a niche but strategically important area—devices in U.S. clinical trials for transcatheter treatment of aortic regurgitation—removing what had been viewed as an incremental future growth lever for Edwards. (medtechdive.com)
3. What it means from here: back to core execution and upcoming catalysts
With M&A no longer the near-term bridge, investor attention shifts back to Edwards’ core franchises and milestones, including TAVR growth expectations for 2026 and progress in mitral/tricuspid therapies. Recent conference commentary highlighted expectations for 2026 TAVR growth alongside the company’s broader strategy and product cadence, which now carry more weight in determining whether EW can re-accelerate without the abandoned acquisition. (investing.com)